Imunon financials
$1.34−3.26%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$2.8M | -$4.3M | -$4.3M | -$3.5M | -$2.8M | -$4.1M | -$4.1M | -$5.0M | -$5.0M | -$5.0M | -$6.0M | -$3.9M |
| Net income | -$2.8M | -$4.2M | -$4.2M | -$3.4M | -$2.7M | -$4.1M | -$4.1M | -$4.8M | -$4.8M | -$4.9M | -$4.9M | -$3.5M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.54 | $-0.84 | $-1.42 | $-1.16 | $-2.15 | $-3.15 | $-1.52 | $-3.76 | $-6.64 | $-6.78 | $-6.79 | $-4.83 |
| EBITDA | -$2.7M | -$4.2M | -$4.2M | -$3.4M | -$2.7M | -$4.1M | -$4.1M | -$4.9M | -$4.9M | -$4.9M | -$5.9M | -$3.8M |
| Operating cash flow | -$3.0M | -$4.0M | -$3.7M | -$4.4M | -$3.0M | -$2.8M | -$4.4M | -$4.1M | -$4.5M | -$5.9M | -$3.8M | -$4.5M |
| Free cash flow | -$3.1M | -$4.0M | -$3.7M | -$4.4M | -$3.0M | -$3.1M | -$4.4M | -$4.1M | -$4.5M | -$5.9M | -$3.8M | -$4.7M |
| Diluted shares | 5.2M | 5.0M | 3.0M | 2.9M | 1.3M | 1.3M | 2.7M | 1.3M | 0.7M | 0.7M | 0.7M | 0.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $6.9M | $4.8M | $8.8M | $5.3M | $4.7M | $2.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $7.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $15.0M | $8.0M | $12.3M | $9.0M | $8.8M | $6.9M |
| Total liabilities | $10.8M | $4.7M | $5.2M | $4.9M | $6.1M | $6.4M |
| Shareholders' equity | $4.2M | $3.4M | $7.1M | $4.1M | $2.7M | $452.0K |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology